Subtype
Benign Peripheral Nervous System Neoplasm
CI-CAN-00000532Explore in graph →
Non-malignant21 active trials2 evidence items
- NCIt
- C213862
Loading cancer entity…
Subtype
CI-CAN-00000532Explore in graph →
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT06360406 | Real-World Treatment Study of Koselugo (Selumetinib) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06502171 | Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas(NF113) | recruiting | Phase 1 | 30 | Girish Dhall, MDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06880991 | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study | recruiting | — | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06188741 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1(NF114) | recruiting | Phase 2 | 200 | University of Alabama at BirminghamOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07407803 | Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas | recruiting | Phase 3 | 177 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours(BIOPORTAL) | recruiting | N/A | 600 | Institut CurieOTHER | 4 | Jul 22, 2025 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05199376 | Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1(CryoNF1) | recruiting | N/A | 30 | Centre Leon BerardOTHER | 1 | Feb 9, 2024 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials